Kidswell Bio Corporation (TYO:4584)

Market Cap	12.15B +182.0%
Revenue (ttm)	6.61B +321.2%
Net Income	280.00M
EPS	6.19
Shares Out	49.60M
PE Ratio	39.56
Forward PE	16.55
Dividend	n/a
Ex-Dividend Date	n/a

Volume	662,900
Average Volume	2,711,780
Open	247.00
Previous Close	248.00
Day's Range	238.00 - 248.00
52-Week Range	93.00 - 417.00
Beta	1.21
RSI	49.83
Earnings Date	Feb 12, 2026

About Kidswell Bio

Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company pipeline products also include GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The com...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 37
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4584

Financial Performance

In fiscal year 2025, Kidswell Bio's revenue was 5.08 billion, an increase of 223.90% compared to the previous year's 1.57 billion. Losses were -21.00 million, -96.07% less than in 2022.